Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Granisetron transdermal patch versus oral granisetron for chemotherapy-induced nausea and vomiting during multi-day chemotherapy
2005-005003-41Phase 3Terminated
- Sponsor
- ProStrakan
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granisetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by ProStrakan. Primary endpoint: Complete control of chemotherapy-induced nausea and vomiting. Started Feb 2006; status: terminated.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2005-005003-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005003-41.